Emma Bush has been appointment as CNX Therapeutics’ Vice President, Commercial, effective as of 9 September 2025. Bush brings extensive global pharmaceutical and healthcare experience to the company, having most recently served as Head of Global Accounts & Business Services at Galderma SA.
Bush has a proven track record in strategic account management at leading companies including GSK and Teva, and she has demonstrated expertise in driving growth across pharmaceuticals, aesthetics and consumer health sectors.
“It’s inspiring to join a company that combines commercial ambition with a genuine commitment to improving patient access to essential medicines,” said Bush. “I look forward to working with the team to build on the strong foundation at CNX and drive our ambitious growth strategy across global markets.”
Guy Clark, CEO of CNX Therapeutics, commented: “We are thrilled to have Emma join CNX at this pivotal point in our growth journey. Her unique combination of global pharmaceutical experience and proven ability to build high-performing commercial organisations aligns perfectly with our strategic priorities. She will be instrumental in executing our plans and strengthening our market position.”
CNX Therapeutics is a speciality pharmaceutical company committed to improving the lives of patients by providing access to essential medicines. The company commercialises and distributes a portfolio of pharmaceuticals for neurological, psychiatric and hospital emergencies in over 60 markets worldwide, both directly and through strategic partnerships.